Resources

Oct 29, 2026

FRONTEO and Maruho Launch Second Co-creation Project for Drug Target Identification in Dermatology

Aiming to Accelerate the Creation of Innovative Drugs Through the Discovery of Novel Targets and the Development of Evidence-Based Mechanistic Hypotheses

Oct 13, 2026

FRONTEO’s Medical Paper Search AI “KIBIT Amanogawa” Adopted by Suntory Global Innovation Center

Leveraging Insights from Medical and Life Science for Research in the Food and Health Sectors

Oct 7, 2026

FRONTEO and ER Stress Research Institute Launch a Project to Discover Biomarkers for Patient Stratification Using Drug Discovery AI Factory

Aiming to Create Innovative Pharmaceuticals by Combining AI-Driven Drug Discovery with Research on Unfolded Protein Response, a Field Associated with Potential Candidates for the Nobel Prize in Physiology or Medicine

Jul 23, 2026

FRONTEO Joins AMED’s “Dementia Research and Development Project” with Oita University and Beppu City

Developing and Evaluating a New Model Using the Equation-Driven AI "KIBIT" for the Early Detection of Alzheimer's Disease, Which Begins Approximately 20 Years Before Onset— Demonstrated Through a Cohort Study of Approximately 800 Beppu Residents —

Jul 16, 2026

FRONTEO and Santen Pharmaceutical Launch Second Co-creation Project

Driving Pipeline Expansion in the Ophthalmology Field Using the AI-powered Drug Discovery Support Service "Drug Discovery AI Factory"

FRONTEO Develops Predictive Model with Daiichi Sankyo to Automatically Extract Toxicological Interpretations from Toxicity Test Reportsのサムネイル

Jul 14, 2026

FRONTEO and Daiichi Sankyo Develop Predictive Model to Automatically Extract Toxicological Interpretations from Toxicity Test Reports

Results presented at the 53rd Annual Meeting of the Japanese Society of Toxicology, utilizing the AI-driven drug discovery support service "Drug Discovery AI Factory"

Jul 7, 2026

FRONTEO Launches Research Support Program to Provide “KIBIT Amanogawa” Medical Paper Search AI to Universities and Research Institutions for One Year

Launches “KIBIT Amanogawa for Academia Program” to Support Academic Research; Up to 10 Projects to Be Selected to Accelerate the Creation of Innovative Pharmaceuticals Originating in Japan

Jun 30, 2026

Masahiro Morimoto, President & CEO of FRONTEO, Delivers a Lecture at American University in Washington, D.C.

Highlights the Value of Human-Centered AI and the Competitive Advantage of “KIBIT” in Supporting Scientific Discovery

Jun 2, 2026

Morimoto, CEO, Delivers Special Lecture at “Growth Strategy for Healthcare Annual Forum 2026,” Attended by Nobel Laureates, Ministers, and 500 CEOs, Leaders from Industry, Academia, and Government

May 28, 2026

FRONTEO and SCOHIA PHARMA Sign Agreement to Explore New Indications Using the AI Drug Discovery Support Service “DDAIF”

May 13, 2026

The University of Oklahoma confirms inhibition of cell proliferation with a novel candidate target molecule for pancreatic cancer discovered by FRONTEO's AI drug discovery support service, Drug Discovery AI Factory

Aiming to develop drugs that meet unmet medical needs by advancing to animal testing in the future

May 13, 2026

FRONTEO Opens KIBIT AI Biology Lab, a Center for AI Drug Discovery

Major update of the AI drug discovery support service Drug Discovery AI Factory and full-scale operation of the system that handles the upstream of the drug discovery value chain

1 2